Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 16, 2021

SELL
$17.83 - $22.29 $221,947 - $277,465
-12,448 Closed
0 $0
Q3 2020

Nov 12, 2020

SELL
$15.78 - $20.82 $47,182 - $62,251
-2,990 Reduced 19.37%
12,448 $259,000
Q2 2020

Aug 13, 2020

BUY
$15.49 - $23.51 $2,292 - $3,479
148 Added 0.97%
15,438 $270,000
Q1 2020

May 13, 2020

BUY
$13.89 - $25.45 $22,307 - $40,872
1,606 Added 11.74%
15,290 $250,000
Q4 2019

Feb 14, 2020

BUY
$10.7 - $22.24 $3,916 - $8,139
366 Added 2.75%
13,684 $282,000
Q3 2019

Nov 08, 2019

BUY
$10.16 - $13.28 $135,310 - $176,863
13,318 New
13,318 $153,000

Others Institutions Holding COLL

About COLLEGIUM PHARMACEUTICAL, INC


  • Ticker COLL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 34,126,200
  • Market Cap $1.12B
  • Description
  • Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...
More about COLL
Track This Portfolio

Track First Republic Investment Management, Inc. Portfolio

Follow First Republic Investment Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Republic Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Republic Investment Management, Inc. with notifications on news.